Vor Bio, a clinical-stage cell and genome engineering company, has appointed Mr. Erez Kalir to its Board of Directors, creating a new seat following a recent private investment in public equity (PIPE) ...

Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today announced the appointment of Robert Warner to its board of directors. Mr.

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing ...

John Crowley, the longtime leader of rare disease drug developer Amicus Therapeutics and a board member of the Biotechnology Innovation Organization, will become the trade organization’s new president ...

PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today ...

DURHAM, N.C.--(BUSINESS WIRE)--Oerth Bio (pronounced “Earth”), an agricultural biotech company pioneering targeted protein modulation for plant health applications, has appointed Thong Q. Le as an ...

Vor Bio (VOR) announced the appointment of Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board of Directors, which has been created in connection with the ...

As an advisor to boards and a former executive recruiter, I’ve read thousands of bios and résumés over my career. OK, if I'm being really honest, I've skimmed thousands of bios and résumés over my ...

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its ...

CAMBRIDGE, England--(BUSINESS WIRE)--Cell coding company bit.bio today announces the addition of its early stage investor Weslie Janeway as a Board member. With her extensive experience on both ...

MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...